Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Tacrolimus-induced hypertension and nephrotoxicity in Fawn-Hooded rats are attenuated by dual inhibition of renin-angiotensin system

L. Hošková, I. Málek, J. Kautzner, E. Honsová, RP. van Dokkum, Z. Husková, A. Vojtíšková, S. Varcabová, L. Cervenka, L. Kopkan,

. 2014 ; 37 (8) : 724-732.

Language English Country England, Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc15023492

Grant support
NT11262 MZ0 CEP Register
NT12171 MZ0 CEP Register

Chronic immunosuppressive therapy is often complicated by the development of both arterial hypertension and renal dysfunction. The principal aim of this study was to assess the effects of dual inhibition of renin-angiotensin system (RAS) and other antihypertensive treatment on blood pressure and renal function in normotensive and hypertensive Fawn-Hooded (FH) strains during chronic calcineurin inhibitor (CNI) administration. Combinations of perindopril (5 mg kg(-1) per day) and losartan (50 mg kg(-1) per day) or amlodipine (6 mg kg(-1) per day) and metoprolol (80 mg kg(-1) per day) were administered to normotensive (FHL) and hypertensive (FHH) rats, fed with diet containing tacrolimus (Tac; 12 mg kg(-1) per day). Tac-induced arterial hypertension in both animal strains (FHL: 151±4; FHH: 198±6 mm Hg) was prevented by dual RAS inhibition (FHL: 132±3 mm Hg, P<0.05; FHH: 153±3 mm Hg, P<0.05) as well as by a combination of amlodipine and metoprolol (FHL: 136±3 mm Hg, P<0.05; FHH: 166±4 mm Hg, P<0.05). However, significant nephroprotection was observed only in animals on dual RAS inhibition where albuminuria was reduced in both FHL (51.1±3.9 vs. 68.3±4.5 μg per day; P<0.05) and FHH rats (13.1±0.3 vs. 18.8±0.7 mg per day; P<0.05). We also found Tac-induced enhancement in renal angiotensin II activity that was significantly reduced by dual RAS inhibition in both FHL (63.5±3.2 vs. 23.1±3.0 fmol g(-1)) and FHH (79.8±8.5 vs. 32.2±5.8 fmol g(-1)). In addition, histological analysis revealed that RAS inhibition noticeably diminished glomerulosclerosis and tubulo-interstitial injury. This study indicates that dual blockade of RAS significantly attenuates Tac-induced arterial hypertension and nephrotoxicity in FH rats and further supports the notion that RAS inhibitors display efficient renoprotective properties during CNI treatment.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc15023492
003      
CZ-PrNML
005      
20191024104702.0
007      
ta
008      
150709s2014 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/hr.2014.79 $2 doi
035    __
$a (PubMed)24718302
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Hošková, Lenka $u Department of Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic. $7 xx0076892
245    10
$a Tacrolimus-induced hypertension and nephrotoxicity in Fawn-Hooded rats are attenuated by dual inhibition of renin-angiotensin system / $c L. Hošková, I. Málek, J. Kautzner, E. Honsová, RP. van Dokkum, Z. Husková, A. Vojtíšková, S. Varcabová, L. Cervenka, L. Kopkan,
520    9_
$a Chronic immunosuppressive therapy is often complicated by the development of both arterial hypertension and renal dysfunction. The principal aim of this study was to assess the effects of dual inhibition of renin-angiotensin system (RAS) and other antihypertensive treatment on blood pressure and renal function in normotensive and hypertensive Fawn-Hooded (FH) strains during chronic calcineurin inhibitor (CNI) administration. Combinations of perindopril (5 mg kg(-1) per day) and losartan (50 mg kg(-1) per day) or amlodipine (6 mg kg(-1) per day) and metoprolol (80 mg kg(-1) per day) were administered to normotensive (FHL) and hypertensive (FHH) rats, fed with diet containing tacrolimus (Tac; 12 mg kg(-1) per day). Tac-induced arterial hypertension in both animal strains (FHL: 151±4; FHH: 198±6 mm Hg) was prevented by dual RAS inhibition (FHL: 132±3 mm Hg, P<0.05; FHH: 153±3 mm Hg, P<0.05) as well as by a combination of amlodipine and metoprolol (FHL: 136±3 mm Hg, P<0.05; FHH: 166±4 mm Hg, P<0.05). However, significant nephroprotection was observed only in animals on dual RAS inhibition where albuminuria was reduced in both FHL (51.1±3.9 vs. 68.3±4.5 μg per day; P<0.05) and FHH rats (13.1±0.3 vs. 18.8±0.7 mg per day; P<0.05). We also found Tac-induced enhancement in renal angiotensin II activity that was significantly reduced by dual RAS inhibition in both FHL (63.5±3.2 vs. 23.1±3.0 fmol g(-1)) and FHH (79.8±8.5 vs. 32.2±5.8 fmol g(-1)). In addition, histological analysis revealed that RAS inhibition noticeably diminished glomerulosclerosis and tubulo-interstitial injury. This study indicates that dual blockade of RAS significantly attenuates Tac-induced arterial hypertension and nephrotoxicity in FH rats and further supports the notion that RAS inhibitors display efficient renoprotective properties during CNI treatment.
650    _2
$a akutní poškození ledvin $x chemicky indukované $x prevence a kontrola $7 D058186
650    _2
$a beta blokátory $x farmakologie $7 D000319
650    _2
$a blokátory receptorů AT1 pro angiotensin II $x farmakologie $7 D047228
650    _2
$a inhibitory ACE $x farmakologie $7 D000806
650    _2
$a zvířata $7 D000818
650    _2
$a kalcineurin $x účinky léků $7 D019703
650    _2
$a blokátory kalciových kanálů $x farmakologie $7 D002121
650    _2
$a dieta $7 D004032
650    _2
$a imunosupresiva $x antagonisté a inhibitory $x toxicita $7 D007166
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a krysa rodu Rattus $7 D051381
650    _2
$a renin-angiotensin systém $x účinky léků $7 D012084
650    _2
$a takrolimus $x antagonisté a inhibitory $x toxicita $7 D016559
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Málek, Ivan, $u Department of Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic. $d 1942- $7 nlk20030129885
700    1_
$a Kautzner, Josef, $u Department of Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic. $d 1957- $7 xx0037112
700    1_
$a Honsová, Eva, $u Department of Clinical and Transplant Pathology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic. $d 1956- $7 xx0075648
700    1_
$a van Dokkum, Richard P E $u Department of Clinical Pharmacology, University Medical Center Groningen, Groningen, The Netherlands.
700    1_
$a Husková, Zuzana, $u Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic. $d 1978- $7 xx0074206
700    1_
$a Vojtíšková, Alžbeta $u Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
700    1_
$a Varcabová, Šárka $u Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
700    1_
$a Červenka, Luděk, $u Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic. $d 1967- $7 xx0037105
700    1_
$a Kopkan, Libor $u Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic. $7 xx0107287
773    0_
$w MED00006041 $t Hypertension research official journal of the Japanese Society of Hypertension $x 1348-4214 $g Roč. 37, č. 8 (2014), s. 724-732
856    41
$u https://pubmed.ncbi.nlm.nih.gov/24718302 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20150709 $b ABA008
991    __
$a 20191024105137 $b ABA008
999    __
$a ok $b bmc $g 1083829 $s 906485
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2014 $b 37 $c 8 $d 724-732 $i 1348-4214 $m Hypertension research $n Hypertens Res $x MED00006041
GRA    __
$a NT11262 $p MZ0
GRA    __
$a NT12171 $p MZ0
LZP    __
$a Pubmed-20150709

Find record

Citation metrics

Archiving options